
Figure S1. Design of Study 201 (Core and OLE)



AD, Alzheimer's disease; IV, intravenous; MCI, mild cognitive impairment; OLE, open label extension




Figure S2. Goodness-of-fit plots for the final lecanemab PK model

400

200

200

400

Individual Predicted Lecanemab Conc (ug/mL)

The gray line is the line of unity (predictions match observed) and the blue line is a linear regression line.

800

500

Time After Dose (h)

250

7**5**0

1000

600

Figure S3. Prediction-corrected visual predictive check plots of observed and predicted lecanemab concentrations for final PK model stratified by study (Top Left= 101; Top Right = 104; Bottom = 201)

